Completion of Preclinical Studies and Phase 2b IND Approval of J2H-1702, a MASH Drug Candidate

J2H Biotech

J2H BIOTECH

METABOLIC | **Preclinical**

Product Type	Small molecules
Indication	Metabolic-Associated Steatohepatitis (MASH)
Target	11β-HSD1 inhibitor
MoA(Mechanism of Action)	
Competitiveness	
Development Stage	Preclinical
Route of Administration	Oral Once-Daily Tablet

J2H-1702 (12W, 11β-HSD1, Oral, QD)	Resmetirom (12W, THR-β, Oral, QD)	Efruxifermin (12W, FGF21, SC, QW)
J2H BIOTECH	Madrigal	akero (a Novo Nordisk company)
Adults with MASH, mainly F2-F3	Adults with MASH, F1-F3	Adults with MASH, F1-F3
Key Efficacy • Liver fat (MRI-PDFF) ↓ • ALT, GGT ↓ • LDL-C ↓ • Body Weight ↓ • **Antifibrotic signal (MRE)** • HbA1c ↓ **Safety** • Favorable short-term tolerability • Low CNS/endocrine liability	**Key Efficacy** • Liver fat (MRI-PDFF) ↓ • ALT ↓ • LDL-C ↓ **Safety** • Mild GI AEs (diarrhea, nausea) • No major safety signals	**Key Efficacy** • Liver fat (MRI-PDFF) ↓ • Weight ↓ • **≥1-stage Fibrosis improvement** (21+weeks) **Limitations** • **Injectable-only** regimen • Class tolerability issues
Metabolic, Inflammatory, Fibrotic	Liver fat, LDL-C	Metabolic, Late Fibrosis
	Ref. The Lancet 2019, 394, 2012–2024.	*Ref. Nature medicine* 2021, 27,1262–1271.

Any unauthorized distribution or reproduction of this material is strictly prohibited.